Xbrane Biopharma AB (publ) ('Xbrane' or 'the Company') (Nasdaq Stockholm: XBRANE), invites to a teleconference for investors, analysts and media on Thursday, February 24, 2022, at 10.00 a.m. CET. Xbrane will publish the company's Year-end report 2021, on Thursday, February 24, 2022, at 8.00 a.m. CET.

Martin Amark, CEO, and Anette Lindqvist, CFO/IR, will present the Year-end report 2021, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link: https://edge.media-server.com/mmc/p/43thqez6

Confirmation Code: 688 50 49

Standard international: +44 (0) 2071 928 338

UK (Local): +44 (0) 844 481 97 52

UK (Tollfree): +44 (0) 800 279 66 19

Sweden (Local): +46 (0) 856 618 467

Sweden (TollFree): +46 (0) 20 012 51 60

US (Local): +1 646 741 31 67

US (TollFree): +1 877 870 91 35

Contact:

Martin Amark

CEO

M: +46 76 309 37 77

E: martin.amark@xbrane.com

Anette Lindqvist

CFO/IR

M: +46 76 325 60 90

E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR28 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

(C) 2022 Electronic News Publishing, source ENP Newswire